- Conditions
- Atherosclerosis, Peripheral Artery Disease, Intermittent Claudication, Chronic Total Aterial Occlusion
- Interventions
- MS-325 Injection (Gadofosveset Trisodium)
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 2:47 AM EDT